News

When admitted to the intensive care unit (ICU), chances are high that the patient has an existing condition in addition to the affliction causing their admittance to the ICU. It is vital that these existing conditions be considered by clinicians when developing a course of treatment, as many times…

A recent study, entitled “The use of antidepressants and the risk of idiopathic pulmonary arterial hypertension,” which is set to be published in The Canadian Journal of Cardiology by Dr. Benjamin D. Fox, of the Centre for Clinical Epidemiology, Jewish General Hospital, and collaborators, addresses the…

A new study entitled “Improved survival of Korean patients with idiopathic pulmonary arterial hypertension after the introduction of targeted therapies” published in August issue of the Heart & Lung journal reports targeted therapies for treatment of idiopathic pulmonary arterial hypertension (IPAH) significantly improve IPAH patients’ survival. IPAH is a serious condition characterized by increased blood pressure in pulmonary arteries, frequently culminating in heart failure. Despite several approved treatments, IPAH currently has no cure, and treatments tend to treat symptoms of the disease rather than the underlying cause. Previously, IPAH conventional treatments included oxygen supplementation to fight the lack of oxygen due to pulmonary vaso constriction, anticoagulants to prevent vascular thrombosis associated with IPAH, as well as digoxin and diuretics. However, data concerning survival rates among IPAH patients who are prescribed these treatments are lacking in…

One of the fundamental steps to gaining more support for much-needed research and development is to first raise awareness among the general public and potential investors. One of the most effective means of rallying support is to publish inspiring stories about people living with a…

The Maryland-based Pulmonary Hypertension Association (PHA), the most prominent organization in the country committed to the prevention, research, education, and advocacy of pulmonary hypertension (PH), has just announced that it has accredited the first 6 Pulmonary Hypertension Care Centers (PHCC) in the US, as part of its…

A new study, entitled “Frequency of Supraventricular Arrhythmias in Patients With Idiopathic Pulmonary Arterial Hypertension” published in the American Journal of Cardiology reports that Supraventricular arrhythmias (SVAs) are associated with a higher risk of death in patients suffering from pulmonary arterial hypertension, and restoration of…

Patients who show signs of pulmonary hypertension are reliably diagnosed non-invasively at the doctor’s office using Doppler echocardiography, a form of ultrasound. A group of researchers at the University of Heidelberg in Germany conducted a study of 1695 patients and determined that Doppler echocardiography reliably assessed systolic pulmonary artery…

The 6th Annual North Carolina Research Triangle Pulmonary Hypertension Symposium will be held on November 7th at the DoubleTree by Hilton Hotel Raleigh-Durham Airport in Research Triangle Park, from 7am to 4pm. The event is endorsed by the American Thoracic Society, sponsored by the Duke University School of…

Clinical application of sildenafil, a phosphodiesterase inhibitor studied for efficacy in treating pulmonary hypertension, to a patient with systemic sclerosis gave meaningful data that support results of basic laboratory research on sildenafil. The patient, a 40 year old female with diffuse…

Promedior Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, has announced that retrospective quantitative imaging data from the company’s Phase 1b clinical trial of the drug PRM-151 for treatment of idiopathic pulmonary fibrosis (IPF), was presented in a poster at the 18th…

New research suggests administering molecular Hydrogen, an antioxidant, orally via Hydrogen water may offer therapeutic value to Pulmonary Hypertension patients. Pulmonary hypertension (PH) is a condition caused by increased pressure in the pulmonary arteries. In advanced cases, its symptoms (shortness of breath, tiredness, chest pain) worsen and may limit…

New insights into the molecular mechanisms of chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (iPAH) generally lead to new avenues of research for treatments that may work better than existing treatments or open the doors for previously untreatable patients. Work from Medical University Vienna in Austria,…